Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

advanced medtech solutions private limited p-21-22, 25-26, 34-35, gidc manjusar, taluka-savli, district-vadodara 391775 gujarat india -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

advanced medtech solutions private limited p-21-22, 25-26, 34-35, gidc manjusar, taluka-savli, district-vadodara 391775 gujarat india -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

alcon laboratories inc. 6201 south freeway 76134-2099 fort worth, tx spojené štáty americké -

Európska únia - slovenčina - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - neoplazmy žalúdka - antineoplastické činidlá - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Európska únia - slovenčina - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - karcinóm, šquamózna bunka - antineoplastické činidlá - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medtronic advanced energy llc 180 international drive 03801 postmounth, nh spojené štáty americké -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medtronic advanced energy llc 180 international drive 03801 postmounth, nh spojené štáty americké -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ligament advanced reinforcement system sa 5 rue de la fontaine 21560 arc sur tille francúzsko -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

mtre advanced technologies ltd 4hayarden street, 81228-76100 yavne, pob 102 izrael -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

medtronic advanced energy llc 180 international drive 03801 postmounth, nh spojené štáty americké -